title: Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
abstract: OBJECTIVE
  To assess the ability of positron emission tomography (PET) scans in differentiating between necrosis and viable seminoma in postchemotherapy (PC) residual disease.
  
  
  METHODS
  We conducted a prospective study of 29 patients with seminoma at Indiana University. All patients had PC residual disease. Computed tomography and PET scans were performed for 19 patients after primary chemotherapy (group A) and for 10 patients after salvage chemotherapy (group B).
  
  
  RESULTS
  In group A, the PC masses were >/= 3 cm in 14 patients, less than 3 cm in three patients, and not quantified in two patients. All of the patients in group A had negative PET scan results and have had stable or decreasing residual mass size (median follow-up duration, 11.5 months; range, 6 to 26 months). In group B, the PC masses were >/= 3 cm in four patients, less than 3 cm in five patients, and not quantified in one patient. One patient had a positive PET scan result for a posterior mediastinal mass. Pathologic diagnosis of the PET-positive mass showed only necrotic tissue. The same patient had a negative PET scan of the retroperitoneal mass but relapsed in that area. Overall, of patients in group B, five have stable or decreasing mass (median follow-up duration, 8 months; range, 7 to 22 months), and five had relapsed disease.
  
  
  CONCLUSIONS
  PET scans have no apparent benefit in PC evaluation of residual masses in bulky seminoma.
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, Indiana University Medical Center, Indianapolis, IN, USA.
authors.forename: K N
authors.initials: KN
authors.lastname: Ganjoo
authors.forename: R J
authors.initials: RJ
authors.lastname: Chan
authors.forename: M
authors.initials: M
authors.lastname: Sharma
authors.forename: L H
authors.initials: LH
authors.lastname: Einhorn
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D009336:Necrosis; D011446:Prospective Studies; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000473:pathology; D016879:Salvage Therapy; D018239:Seminoma / Q000188:drug therapy* / Q000473:pathology*; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000473:pathology; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D007069:Ifosfamide